<?xml version='1.0' encoding='utf-8'?>
<document id="30191262"><sentence text="The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women."><entity charOffset="14-24" id="DDI-PubMed.30191262.s1.e0" text="laquinimod" /><entity charOffset="122-138" id="DDI-PubMed.30191262.s1.e1" text="ethinylestradiol" /><entity charOffset="143-157" id="DDI-PubMed.30191262.s1.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.30191262.s1.e0" e2="DDI-PubMed.30191262.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30191262.s1.e0" e2="DDI-PubMed.30191262.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30191262.s1.e0" e2="DDI-PubMed.30191262.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30191262.s1.e1" e2="DDI-PubMed.30191262.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30191262.s1.e1" e2="DDI-PubMed.30191262.s1.e2" /></sentence><sentence text="Laquinimod is an orally dosed immuno-modulator currently under development for Huntington's disease (HD)"><entity charOffset="0-10" id="DDI-PubMed.30191262.s2.e0" text="Laquinimod" /></sentence><sentence text=" Preclinical findings suggest potential teratogenicity of laquinimod, thus the reproductive ability of females with HD treated with laquinimod needs to be closely managed"><entity charOffset="58-68" id="DDI-PubMed.30191262.s3.e0" text="laquinimod" /><entity charOffset="132-142" id="DDI-PubMed.30191262.s3.e1" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.30191262.s3.e0" e2="DDI-PubMed.30191262.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30191262.s3.e0" e2="DDI-PubMed.30191262.s3.e1" /></sentence><sentence text=" Because combined oral contraceptives (COC) are often used in this context, the pharmacokinetics of COC containing ethinylestradiol (EE) and levonorgestrel (LNG) in combination with laquinimod (0"><entity charOffset="115-131" id="DDI-PubMed.30191262.s4.e0" text="ethinylestradiol" /><entity charOffset="133-135" id="DDI-PubMed.30191262.s4.e1" text="EE" /><entity charOffset="141-155" id="DDI-PubMed.30191262.s4.e2" text="levonorgestrel" /><entity charOffset="157-160" id="DDI-PubMed.30191262.s4.e3" text="LNG" /><entity charOffset="182-192" id="DDI-PubMed.30191262.s4.e4" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e0" e2="DDI-PubMed.30191262.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e0" e2="DDI-PubMed.30191262.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e0" e2="DDI-PubMed.30191262.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e0" e2="DDI-PubMed.30191262.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e0" e2="DDI-PubMed.30191262.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e1" e2="DDI-PubMed.30191262.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e1" e2="DDI-PubMed.30191262.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e1" e2="DDI-PubMed.30191262.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e1" e2="DDI-PubMed.30191262.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e2" e2="DDI-PubMed.30191262.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e2" e2="DDI-PubMed.30191262.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e2" e2="DDI-PubMed.30191262.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e3" e2="DDI-PubMed.30191262.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30191262.s4.e3" e2="DDI-PubMed.30191262.s4.e4" /></sentence><sentence text="6 mg/day) was evaluated" /><sentence text="" /><sentence text="In this randomized, phase-1 single-center, double-blind, placebo-controlled, 2-way crossover drug-drug interaction (DDI) study in 48 healthy premenopausal women, COC were administered in a 28-day regimen of 21 days followed by 7 pill-free days for 4 cycles and laquinimod or placebo was administered for 28 days in cycle 1 and cycle 3 starting 7 days prior to COC administration"><entity charOffset="261-271" id="DDI-PubMed.30191262.s7.e0" text="laquinimod" /></sentence><sentence text=" Blood samples for pharmacokinetic profiling of laquinimod, EE and LNG were collected on day 21 and day 22 of Cycles 1 and 3 pre-dose and multiple times post-dose"><entity charOffset="48-58" id="DDI-PubMed.30191262.s8.e0" text="laquinimod" /><entity charOffset="60-69" id="DDI-PubMed.30191262.s8.e1" text="EE" /><entity charOffset="67-76" id="DDI-PubMed.30191262.s8.e2" text="LNG" /><pair ddi="false" e1="DDI-PubMed.30191262.s8.e0" e2="DDI-PubMed.30191262.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30191262.s8.e0" e2="DDI-PubMed.30191262.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30191262.s8.e0" e2="DDI-PubMed.30191262.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30191262.s8.e1" e2="DDI-PubMed.30191262.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30191262.s8.e1" e2="DDI-PubMed.30191262.s8.e2" /></sentence><sentence text="" /><sentence text="The ratio of geometric means and 90% confidence intervals for AUC0-24 and Cmax of EE and LNG with and without laquinimod were all within the bioequivalence range (80 to 125%)"><entity charOffset="110-120" id="DDI-PubMed.30191262.s10.e0" text="laquinimod" /><entity charOffset="82-91" id="DDI-PubMed.30191262.s10.e1" text="EE" /><entity charOffset="89-98" id="DDI-PubMed.30191262.s10.e2" text="LNG" /><pair ddi="false" e1="DDI-PubMed.30191262.s10.e1" e2="DDI-PubMed.30191262.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30191262.s10.e1" e2="DDI-PubMed.30191262.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30191262.s10.e1" e2="DDI-PubMed.30191262.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30191262.s10.e2" e2="DDI-PubMed.30191262.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30191262.s10.e2" e2="DDI-PubMed.30191262.s10.e0" /></sentence><sentence text=" Laquinimod pharmacokinetics was consistent with those observed in previous studies"><entity charOffset="1-11" id="DDI-PubMed.30191262.s11.e0" text="Laquinimod" /></sentence><sentence text=" The adverse event profile was in line with the current knowledge on the safety profile of both drugs, with headache as the most frequently reported treatment-related adverse event" /><sentence text="" /><sentence text="The combination of COC and laquinimod treatment was found to be safe, tolerable, and devoid of any noticeable pharmacokinetic interaction"><entity charOffset="19-22" id="DDI-PubMed.30191262.s14.e0" text="COC" /><entity charOffset="27-37" id="DDI-PubMed.30191262.s14.e1" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.30191262.s14.e0" e2="DDI-PubMed.30191262.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30191262.s14.e0" e2="DDI-PubMed.30191262.s14.e1" /></sentence><sentence text="" /></document>